Novo Nordisk: Semaglutide fails in Alzheimer's treatment!
Reading Time: 3 minutes
The Danish pharmaceutical company Novo Nordisk faces a significant setback in Alzheimer's research. In two Phase III studies with a total of around 3,800 participants, semaglutide, known from Ozempic, Wegovy, and Rybelsus, could not slow the progression of the neurodegenerative disease in its early stages. Semaglutide showed no significant improvement compared to the placebo group The studies were designed to reduce cognitive decline by at least 20%. However, after two years of treatment, no differences were observed compared to the placebo....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
